314 related articles for article (PubMed ID: 9749589)
41. Effect of deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
[TBL] [Abstract][Full Text] [Related]
42. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
43. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Olanow CW; Mytilineou C; Tatton W
Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
[No Abstract] [Full Text] [Related]
44. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
45. Neuroprotection for Parkinson's disease.
Koller WC
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S155-9. PubMed ID: 9749588
[TBL] [Abstract][Full Text] [Related]
46. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
Rascol O
Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
[TBL] [Abstract][Full Text] [Related]
47. Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
Head J; Ben-Shlomo Y; Lees AJ
Clin Neuropharmacol; 1998; 21(4):265-6. PubMed ID: 9704171
[No Abstract] [Full Text] [Related]
48. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.
Ward CD
J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):217-20. PubMed ID: 8126510
[TBL] [Abstract][Full Text] [Related]
49. Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Ann Neurol; 1996 Jul; 40(1):99-107. PubMed ID: 8687199
[TBL] [Abstract][Full Text] [Related]
50. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
51. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
52. Parkinson's disease therapy: treatment of early and late disease.
Jankovic J
Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
[TBL] [Abstract][Full Text] [Related]
53. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group.
Vatassery GT; Fahn S; Kuskowski MA
Neurology; 1998 Jun; 50(6):1900-2. PubMed ID: 9633757
[TBL] [Abstract][Full Text] [Related]
54. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
55. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V
Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298
[TBL] [Abstract][Full Text] [Related]
56. [What strategies are recommended for early stage disease? Other treatments].
Damier P
Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044
[No Abstract] [Full Text] [Related]
57. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.
Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Lang AE;
Mov Disord; 2008 Apr; 23(5):653-9; quiz 776. PubMed ID: 18076084
[TBL] [Abstract][Full Text] [Related]
58. Study design problems of DATATOP study analysis.
Mäki-Ikola O; Heinonen E
Ann Neurol; 1996 Dec; 40(6):946-8. PubMed ID: 9007106
[No Abstract] [Full Text] [Related]
59. Reexamination of the TEMPO Study.
Shults CW
Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
[No Abstract] [Full Text] [Related]
60. The treatment of Parkinson's disease: current concepts and rationale.
Hingtgen CM; Siemers E
Compr Ther; 1998; 24(11-12):560-6. PubMed ID: 9847972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
